CA2102890A1 - Derives n-carboxyalkylpeptidyles substitues utilises comme agents antidegeneratifs - Google Patents

Derives n-carboxyalkylpeptidyles substitues utilises comme agents antidegeneratifs

Info

Publication number
CA2102890A1
CA2102890A1 CA002102890A CA2102890A CA2102890A1 CA 2102890 A1 CA2102890 A1 CA 2102890A1 CA 002102890 A CA002102890 A CA 002102890A CA 2102890 A CA2102890 A CA 2102890A CA 2102890 A1 CA2102890 A1 CA 2102890A1
Authority
CA
Canada
Prior art keywords
ethyl
carboxy
glycine
phenyl
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002102890A
Other languages
English (en)
Inventor
Soumya P. Sahoo
Scott A. Polo
Philippe L. Durette
Craig K. Esser
William K. Hagmann
Ihor E. Kopka
Kevin T. Chapman
Charles G. Caldwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2102890A1 publication Critical patent/CA2102890A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002102890A 1991-05-28 1992-05-01 Derives n-carboxyalkylpeptidyles substitues utilises comme agents antidegeneratifs Abandoned CA2102890A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70582691A 1991-05-28 1991-05-28
US705,826 1991-05-28
US87390592A 1992-04-24 1992-04-24
US873,905 1992-04-24

Publications (1)

Publication Number Publication Date
CA2102890A1 true CA2102890A1 (fr) 1992-11-29

Family

ID=27107579

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002102890A Abandoned CA2102890A1 (fr) 1991-05-28 1992-05-01 Derives n-carboxyalkylpeptidyles substitues utilises comme agents antidegeneratifs

Country Status (4)

Country Link
EP (1) EP0586537A4 (fr)
JP (1) JPH06508135A (fr)
CA (1) CA2102890A1 (fr)
WO (1) WO1992021360A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5773428A (en) * 1993-08-05 1998-06-30 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
RU2132851C1 (ru) * 1993-08-05 1999-07-10 Синтекс (Ю.Эс.Эй) Инк. Производные амидов, являющиеся ингибиторами матричных металлопротеаз, фармацевтическая композиция
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
PT822186E (pt) * 1994-01-20 2000-08-31 British Biotech Pharm L-tert-leucina-2-piridilamida
AU2361295A (en) * 1994-04-28 1995-11-29 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996033733A1 (fr) * 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Nouveau remede pour affections cutanees
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
ES2233275T3 (es) * 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
IL128337A0 (en) 1996-09-10 2000-01-31 British Biotech Pharm Cytostatic hydroxamic acid derivatives
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6576664B1 (en) 1997-08-18 2003-06-10 Bristol-Myers Squibb Pharma Company Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
AU2001250571A1 (en) * 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
AU2003233154A1 (en) 2002-06-10 2003-12-22 Pfizer Inc. Metabolites of prinomastat and their sythesis
JP2006504796A (ja) * 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性性障害を処置するためのチアゾール化合物
MXPA05012196A (es) * 2003-05-12 2006-02-08 Pfizer Prod Inc Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
US7846963B2 (en) 2003-05-17 2010-12-07 Korea Research Institute Of Bioscience And Biotechnology 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
WO2006117660A2 (fr) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Methode de traitement du cancer et des maladies coronaire, inflammatoire et maculaire combinant la modulation de proteines dependantes du zinc et/ou du cuivre

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
US4568666A (en) * 1984-10-18 1986-02-04 G. D. Searle & Co. Carboxylalkyl peptide derivatives
US4771037A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. N-carboxyalkyl compounds

Also Published As

Publication number Publication date
JPH06508135A (ja) 1994-09-14
EP0586537A4 (en) 1997-06-25
EP0586537A1 (fr) 1994-03-16
WO1992021360A1 (fr) 1992-12-10

Similar Documents

Publication Publication Date Title
CA2102890A1 (fr) Derives n-carboxyalkylpeptidyles substitues utilises comme agents antidegeneratifs
RU2170232C2 (ru) Амиды фосфиновых кислот и способ предупреждения или лечения заболевания, связанного с нежелательной активностью металлопротеазы
US5387610A (en) Peptide derivatives of collagenase inhibitor
FI84472C (fi) Foerfarande foer framstaellning av kollagenasinhibitorer pao basis av hydroxiaminosyra.
US5672583A (en) Carboxy-peptidyl derivatives as antidegenerative active agents
KR100352316B1 (ko) 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
US5679700A (en) Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
SK63194A3 (en) Peptide derivatives
FR2609289A1 (fr) Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
CZ287780B6 (en) Peptide derivatives, their use and pharmaceutical preparation in which they are comprised
JPH10512241A (ja) マトリックス・メタロプロテアーゼのヒドロキサム酸含有阻害剤
JPH10500986A (ja) 金属タンパク質分解酵素阻害剤
US5508266A (en) Gem-disubstituted amino acid derivatives
JP3647914B2 (ja) 環式アミノ酸誘導体
US5506244A (en) Cyclic amino acid derivatives
US5403952A (en) Substituted cyclic derivatives as novel antidegenerative agents
US5629343A (en) N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
US6090785A (en) Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
US5932551A (en) Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative active agents
EP0159396B1 (fr) Dérivés carboxyalkyl peptides
WO1995029689A1 (fr) Derives de n-carboxyalkyle utilises comme agents antidegeneratifs
IE65539B1 (en) Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same
CA2196182A1 (fr) Derives aldehydes utilises comme inhibiteurs de protease d'upsteine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead